Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy.

Diabetes Ther · 2022 · PMC9240142 · PMID 35687260

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, the reduction in AMI was favourable for dapagliflozin but did not reach statistical significance compared with DPP4i (HR 0.91, 95% CI 0.72–1.16) [ 44 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.